Pharma and life sciences · Commercial data and HCP intelligence
Miss the brand plan and the deal waits a year.
You sell HCP, patient, site or access data to commercial, medical affairs and market access teams. Budgets are set in each brand’s plan, from late spring to autumn. Win one brand, and the next one still buys on its own.
- Sales cycle
- 6–12 months Illustrative
- Buying panel
- 5–12 people Illustrative
- First scope
- One brand or function
Updated 5 October 2026 · Based on Panelhop research, October 2026
At a specialty or rare disease brand inside a biopharma company5–12 people Illustrative
The short answer
How do commercial data vendors sell to pharma brand and market access teams?
Commercial data and HCP intelligence vendors sell patient, prescriber, site and access data to biopharma and medtech companies, mostly to biopharma brand, medical affairs and market access teams. By our estimate, deals take 6–12 months and start with one brand or therapy area. A need that misses the brand plan waits for the next cycle, and CRM migrations pause buying.
Commercial data and HCP intelligence · How a deal really moves
The brand lead loves it. Privacy stalls it. One brand buys. The rest of the portfolio buys elsewhere. The same deal, dated to the brand plan. Privacy in before the price, and the next brand mapped early.
One specialty or rare disease brand, 5–12 people and an estimated 6–12 months from first signal to signature.
What opens a deal
- PDUFA date or approval: Milestone · US
- CRM decision and migration: Technology
- Annual brand planning: Budget
- Acquisition closes: Consolidation
- New brand or access leader: Leadership
Signal Desk · weekly: In-market accounts, scored and mapped
Your buyer and who decides
A specialty biopharma brand
Also commercial biotechs and top-tier pharma
72 biotechs with over $500M in sales in 2025
Panel Check · coverage baselined
- Brand or commercial lead, can Veto: Data the field team does not trust or use.
- IT and data, can Veto: Point solutions that add integrations.
- Privacy and compliance, can Veto: Patient data used beyond what its source permits.
- Market access: Patient programmes with no effect shown before renewal.
- Commercial operations: Another data feed to maintain during a CRM migration.
- Medical affairs: Medical insight drifting into promotional use.
How the deal moves
Targeting Typical time: 2–8 weeks
Brand planning
- Where it stalls
- The need misses this year’s brand plan
- With Panelhop: Leak Fix
- Brand-plan window on every deal, the case seeded before budgets lock
First meeting
Evaluation Typical time: 1–3 months
- Where it stalls
- Buyers wait for their CRM migration to end
- With Panelhop: Signal Desk
- CRM choice and cut-over date on every account, worked in that order
Data review
- Where it stalls
- Privacy sees the data sources after the yes
- With Panelhop: Leak Fix
- Privacy, legal and security in before the price is agreed
Pilot Typical time: 2–12 wk, if any
- Where it stalls
- The data works. Nobody owns the rollout.
- With Panelhop: Leak Fix
- Rollout budget owner and success test named before the pilot
Contract Typical time: 1–3 months
Expansion
- Where it stalls
- One brand renews, and the rest buy elsewhere
- With Panelhop: Panel Ops
- Next brands and functions worked as expansion triggers, every month
Panel Ops · monthly: Scores and plays tuned against the baseline
Illustrative Source: Stages, seats, triggers and stalls from Panelhop research, October 2026; EY; the services as described on the Services page. Note: Durations, panel sizes and cycle lengths are Panelhop estimates from our research, not measurements.
At a glance
| Sales cycle | 6–12 months Illustrative |
|---|---|
| Buying panel | 5–12 people Illustrative |
| First scope | One brand or function |
| How deals start | A launch, PDUFA date or new leader, then a demo request |
Source: Panelhop research, October 2026. Note: Values marked Illustrative are Panelhop estimates from our research, not measurements.
Commercial data pipelines leak at the brand and the review.
Why do commercial data deals with biopharma stall?
Commercial data deals stall where one brand champion sells alone, brand plan dates are unknown, CRM migrations are not tracked, privacy review starts late and the next brand is never mapped. Each leak can be dated against the brand calendar.
Where the pipeline leaks: 5 points across 8 stages.
‘Next year’s plan’ means the deal slips a year
- What you see
- Deals slip a year after the champion mentions next year’s plan.
- Why it happens
- Nobody records when each brand sets its budget, so the forecast mixes funded and unfunded deals.
Stage Brand planning
Privacy, IT and procurement arrive after the champion
- What you see
- A brand lead loves the data, then privacy, IT and procurement arrive with questions.
- Why it happens
- Access, IT, privacy and procurement are not mapped early. In our analysis of vendors’ websites, single-threaded deals were a likely bottleneck for all 3 commercial data vendors.
Stage First meeting
‘After our CRM migration’ stalls your evaluation
- What you see
- Commercial teams say ‘after our CRM migration’, and integration questions take over early meetings.
- Why it happens
- Nobody records which CRM each account chose or when it cuts over, so reps work accounts in the wrong order.
Stage Evaluation
A signed-off brand project waits on privacy
- What you see
- A signed-off brand project waits weeks for privacy and security approval.
- Why it happens
- Privacy and security join after the brand team has chosen. In our analysis of vendors’ websites, late security, consent and compliance review was a likely bottleneck for 2 of the 3 commercial data vendors.
Stage Data review
One brand renews while the portfolio buys elsewhere
- What you see
- One brand renews while the rest of the portfolio buys elsewhere.
- Why it happens
- Relationships stay with the first brand team. In our analysis of vendors’ websites, failure to expand beyond one brand or function was a likely bottleneck for all 3 commercial data vendors.
Stage Expansion
Launch dates and brand plans open commercial budgets.
What makes a biopharma brand buy commercial data?
Biopharma brands buy commercial data before a launch or PDUFA date, during annual brand planning, around a CRM decision, after an acquisition and when a new commercial or access leader arrives. Most of these dates surface in discovery or in public filings.
The 5 events that open or close the window for a deal.
Budget cycle
PDUFA date or approval
- What happens
- A biotech’s BLA or NDA is accepted with a PDUFA date, and launch planning starts.
- Where to spot it
- FDA filing announcements, company press releases and investor decks.
- Window
- Opens 6–12 months before the milestone.
Technology
CRM decision and migration
- What happens
- A pharma commercial team chooses a new CRM platform and re-integrates its data, analytics and content tools.
- Where to spot it
- CRM migration job postings, partner commentary and company statements.
- Window
- Adjacent purchases tend to wait for the decision and the cut-over, so engage at the platform decision.
Budget cycle
Annual brand planning
- What happens
- Brand teams at large pharma set next year’s programmes and budgets.
- Where to spot it
- Each brand’s planning calendar, gathered in discovery and kept on the account.
- Window
- Runs from late spring to autumn; a need found after the plan locks waits a year.
Consolidation
Acquisition closes
- What happens
- An acquirer takes over a brand and its data contracts, and decides which vendors to keep.
- Where to spot it
- M&A trackers and closing notices in company filings.
- Window
- Purchases follow 0–12 months after close.
Leadership
New commercial or access leader
- What happens
- A new head of commercial, market access or patient services reviews the data and vendors behind the brand.
- Where to spot it
- Industry appointment roundups and job changes at target accounts.
- Window
- Often opens in the new leader’s first months, as they review the data and vendors behind the brand.
Brand teams buy; privacy and IT can veto.
Who buys HCP and patient data at a biopharma company?
A brand or commercial lead usually sponsors a commercial data purchase, with market access, patient services and commercial operations shaping it. Privacy, legal, IT and procurement review the data sources, consent and fit with the commercial platform, and can slow or stop the deal.
At a specialty or rare disease brand inside a biopharma company, 5–12 people sit on the panel and 3 seats can stop the deal.
At a specialty or rare disease brand inside a biopharma company: 5–12 people
Brand or commercial lead
Can Veto
VP Marketing · Commercial Strategy Lead
- Cares about
- Reaching the right prescribers before and after launch.
- Worries about
- Data the field team does not trust or use.
Market access and patient services
VP Market Access · Director Market Access · Head of Patient Services
- Cares about
- Fewer access barriers and patients who stay on therapy.
- Worries about
- Programmes whose effect on patients cannot be shown before renewal.
Commercial operations
Director Commercial Operations
- Cares about
- Data that flows into the CRM and reporting without manual work.
- Worries about
- Another data feed to maintain during a CRM migration.
Medical affairs
Head of Medical Affairs
- Cares about
- Insight on sites and scientific experts that stays compliant.
- Worries about
- Medical insight drifting into promotional use.
IT and data
Can Veto
Chief Information and Digital Officer · Enterprise Architect
- Cares about
- Fit with the commercial platform and the data model.
- Worries about
- Point solutions that add integrations.
Privacy, legal and compliance
Can Veto
Data Protection Officer · Compliance Officer · Legal Counsel
- Cares about
- A documented basis for every data source under HIPAA or GDPR, and an audit trail of how data is used.
- Worries about
- Patient data used beyond what its source permits.
Procurement
Category Manager · Strategic Sourcing Lead
- Cares about
- Price benchmarks and preferred-vendor status.
- Worries about
- Single-source dependency and price creep.
You sell outcomes to brand and access teams.
What do commercial data vendors sell, and to which biopharma teams?
Commercial data vendors sell prescriber, site, patient and access insight that brand, access and patient services teams use to target prescribers, remove access barriers and track adherence. Vendor sites follow the brand: 2 of the 3 commercial data vendors we analysed have therapy-area or brand-type pages.
What vendors of this type sell
- HCP and site intelligence for targeting and engagement
- Patient journey and specialty pharmacy analytics
- Market access and patient services data and workflows
- Diagnostic and lab data for precision medicine brands
- Data feeds and APIs into the commercial stack
Which biopharma and medtech companies buy it
- Specialty and rare disease brands, including cell and gene therapies
- Commercial-stage biotechs, including a record 72 companies with more than $500M in sales in 2025
- Top-tier biopharma commercial and medical affairs teams
- Market access and patient services functions
Commercial data deals follow the brand calendar.
How does a commercial data deal move at a biopharma company?
A commercial data deal moves from a launch, access problem or new leader through the brand plan, an outcomes evaluation, a privacy review and often a pilot to contract and expansion. By our estimate, most deals take 6–12 months, and the brand plan decides whether money exists this year. Durations show the buyer’s side.
Stage by stage: what you do, what the biopharma or medtech company does, and what changes at the 5 stages where deals stall.
| Stage | What you do | What the biopharma or medtech company does | Today | With Panelhop |
|---|---|---|---|---|
| Targeting Typical time: 2–8 weeks | Segments by therapy area and brand type. | A launch, a PDUFA date, an access problem or a new brand leader creates the need. | Brands are found when a champion fills in a form. | Each week, accounts with a PDUFA date, a launch, a new brand or access leader or a CRM decision arrive in your CRM, scored, with the signal that fired. Signal Desk In-market accounts, weekly |
| Brand planning | Pitches when a champion shows interest, often after budgets are set. | Sets next year’s brand budget in annual planning, from late spring to autumn at large pharma. | Close dates ignore the brand calendar. Stalls: The need misses the brand plan. A need found after the brand plan is set waits for the next cycle, however keen the champion. | A brand-plan window is required on every opportunity, so reps seed the business case with the brand lead before budgets lock, and a deal risk score flags the rest before the forecast call. Leak Fix We build the fixes |
| First meeting | Answers a demo request from one commercial or access champion. | A brand, access or commercial operations lead asks to see outcomes in their therapy area. | Reps meet the champion who asked for a demo. | Each account brief maps access, IT and privacy beside the champion, and suggests a first touch your rep reviews and owns. Signal Desk In-market accounts, weekly |
| Evaluation Typical time: 1–3 months, then 2–6 weeks of references | Shows outcomes and therapy-area case studies. | Tests the data against its own prescribers, patients or sites; IT checks the fit with the CRM. | Reps pitch accounts mid-migration, and the deal waits for the cut-over. Stalls: The CRM migration comes first. Commercial teams defer data and engagement purchases until their CRM decision and migration are done, by our estimate. | Each account brief records the account’s CRM choice and cut-over date, so reps work accounts in the order their windows open. Signal Desk In-market accounts, weekly |
| Data review | Answers security, consent and compliance questions. | Privacy, legal and security review data sources, consent, HIPAA or GDPR terms and hosting. | Privacy first sees the data sources after the yes. Stalls: Consent review after the yes. Privacy and security see the data sources after the brand team has chosen, so the start date slips. | Stage exit criteria bring privacy, legal and security into the deal before the price is agreed. Leak Fix We build the fixes |
| Pilot Typical time: 2–12 weeks where a pilot runs | Runs a pilot on one brand or region. | Tests on one brand, sometimes funded from an innovation or IT budget rather than the brand’s. | Pilots start with no owner for the rollout. Stalls: A pilot with no budget owner. The pilot proves the data works, but nobody owns the budget or the success test for a wider rollout, so it is extended or re-tendered. | A mutual action plan names the budget owner, the success test and the decision date before a pilot starts. Leak Fix We build the fixes |
| Contract Typical time: 1–3 months, then 1–4 weeks for sign-off | Negotiates data licences, refresh rates and integration. | Procurement, legal and finance agree the contract and data terms; the brand or commercial head signs. | Unfunded deals sit in this year’s forecast. | A deal risk score and forecast tracking flag deals without a funded budget line before the forecast call. Leak Fix We build the fixes |
| Expansion | Waits for other brands to ask. | Each brand, therapy area or function buys on its own; procurement reviews spend at renewal. | The next brand waits to be asked. Stalls: One brand, then silence. Relationships sit with the first brand team, and nobody maps the next brand or function before renewal. | Panel Ops operates the expansion triggers for the next brands and functions with your team, reviews signals weekly and reports against the baseline every month. Panel Ops We run it monthly |
Qualify accounts by panel, not by demo request.
How does Panelhop help commercial data vendors sell to biopharma?
Panelhop helps commercial data vendors qualify accounts by fit and engagement across the panel. Signal Desk (in-market accounts, weekly), Leak Fix (we build the fixes) and Panel Ops (we run it monthly) work the stages that leak. Each is measured against a baseline from a Panel Check (GTM audit).
What we baseline and report
- Brands or functions buying per customer account, against the baseline
- Open deals with privacy, IT and procurement engaged, against the baseline
- Days from a PDUFA, launch or leadership signal to your rep’s first touch, against the baseline
Other vendor types in pharma and life sciences.
What other vendors sell to biopharma and medtech companies?
The same biopharma and medtech companies buy from these vendor types too, through different panels and pipelines.
- Vendor type
eClinical software
EDC, eCOA, eConsent, RTSM, CTMS and eTMF platforms sold to trial sponsors and CROs, priced per study, user or portfolio.
Read the pipeline - Vendor type
eQMS and quality management software
Cloud eQMS for document control, training, CAPA, audits and supplier quality, sold to device makers, biotechs, pharma sites and CDMOs.
Read the pipeline - Vendor type
Regulatory information and pharmacovigilance software
RIM, submission, UDI and safety database software sold to regulatory affairs and drug safety teams at biopharma and medtech companies.
Read the pipeline - Vendor type
Lab and manufacturing software
LIMS, ELN, MES and electronic batch record software sold to QC labs, manufacturing sites and CDMOs in pharma, biotech and medtech.
Read the pipeline
The words your buyers use, defined.
What do terms like “HCP” and “PDUFA date” mean?
Plain definitions of the terms that come up when you sell commercial data and HCP intelligence to biopharma and medtech companies.
- HCP
- Healthcare professional: a physician, nurse, pharmacist or other prescriber or influencer of treatment. Commercial and medical teams engage HCPs under strict compliance rules.
- PDUFA date
- The FDA’s target date for acting on a drug or biologic application under the Prescription Drug User Fee Act. Launch planning and launch purchases cluster in the months before it.
- Market access
- The function that secures pricing, reimbursement and payer coverage for a medicine so that eligible patients can get it. Market access teams buy payer, claims and access data.
- Patient services
- Programmes that help patients start and stay on therapy, from benefits checks to adherence support, often run with specialty pharmacies and hub providers.
- Brand plan
- A pharma brand’s annual plan for strategy, programmes and budget, usually set between late spring and autumn at large companies. A vendor outside the plan usually waits for the next cycle.
Answers before your next biopharma or medtech company deal.
What do vendors of commercial data and HCP intelligence ask about selling to biopharma and medtech companies?
When do biotechs buy commercial technology before a PDUFA date?
Biotechs tend to buy commercial data and engagement tools an estimated 6–12 months before a PDUFA date or launch. At that point the launch plan and budget are still open. Vendors that track filing acceptances and PDUFA dates for every biopharma account reach brand and commercial operations heads in that window.
How does a pharma CRM migration affect commercial data vendors?
Pharma commercial teams moving to a new CRM platform tend to defer adjacent data, analytics and engagement purchases until the decision and cut-over are done, by our estimate. Integration questions also dominate early meetings. Commercial data vendors should record each biopharma account’s CRM choice and migration timing, and work accounts in the order their windows open.
Why do commercial data pilots at pharma companies not turn into contracts?
Commercial data pilots at biopharma companies often stall because nobody owns the rollout budget or the success test. The pilot proves the data works on one brand or region, sometimes funded from an innovation or IT budget, and is then extended or re-tendered. Commercial data vendors should agree the budget owner, the success criteria and the decision date in a mutual action plan before the pilot starts.
How do commercial data vendors expand from one brand to the portfolio?
Commercial data vendors expand across a biopharma portfolio by mapping each customer’s other brands, therapy areas and functions before renewal, because each often buys on its own. Relationships that sit only with the first brand team stall growth. In our analysis of life sciences vendors’ websites, none of the 13 shows a portfolio offer. Treat each new brand as an account play with its own buying group.
When do pharma brand teams set their budgets?
Pharma brand teams at large companies set next year’s budgets in the brand plan, which runs from late spring to autumn, by our estimate. A commercial data need found after the plan locks usually waits for the next cycle. Vendors should record each brand’s planning window, seed the business case with the brand lead early and flag unfunded deals in the forecast.
How long does it take to sell commercial data to a pharma company?
Selling commercial data to a biopharma company takes an estimated 6–12 months, longer at top-tier pharma. A brand or commercial lead sponsors the deal, while market access, patient services and commercial operations shape it. Privacy, legal and IT review data sources, consent and CRM fit, and can stop the deal. Deals that miss the brand plan wait for the next cycle.
Where the numbers come from.
Sources
Sourced figures link to their source below. Figures marked Illustrative, and figures given as estimates, are inferred from Panelhop research. Vendors appear only as types, never by name.
- EY, Biotech Beyond Borders Report 2026 (2026)
- Panelhop research, October 2026: our analysis of the vendors, buying panels, pipelines and triggers for commercial data and HCP intelligence in pharma and life sciences, from public sources. Vendor names are not published.
Find where your pipeline to biopharma and medtech companies leaks.
